Barrow, Hanley, Mewhinney & Strauss’s Integra LifeSciences IART Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.94K	Hold	275	–	–	﹤0.01%	295
2026 Q1	$2.59K	Hold	275	–	–	﹤0.01%	317
2025 Q4	$3.42K	Hold	275	–	–	﹤0.01%	290
2025 Q3	$3.94K	Hold	275	–	–	﹤0.01%	290
2025 Q2	$3.37K	Hold	275	–	–	﹤0.01%	276
2025 Q1	$6.05K	Hold	275	–	–	﹤0.01%	245
2024 Q4	$6.24K	Hold	275	–	–	﹤0.01%	256
2024 Q3	$5K	Buy	+275	New	+$6.37K	﹤0.01%	267

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's IART Position: Q2 2026 in Review

Barrow, Hanley, Mewhinney & Strauss held its Integra LifeSciences (IART) position steady in Q2 2026 at 275 shares worth $4.94K. The position accounts for ﹤0.01% of the portfolio, ranked #295.

Barrow, Hanley, Mewhinney & Strauss first reported a position in IART in Q3 2024 and has held it in 8 quarters since. The position peaked at $6.24K in Q4 2024. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

Barrow, Hanley, Mewhinney & Strauss held 275 shares of Integra LifeSciences worth $4.94K as of Q2 2026.
Barrow, Hanley, Mewhinney & Strauss left its Integra LifeSciences share count unchanged in Q2 2026.
Integra LifeSciences made up ﹤0.01% of Barrow, Hanley, Mewhinney & Strauss's portfolio in Q2 2026, its #295 holding.
Barrow, Hanley, Mewhinney & Strauss first reported a position in Integra LifeSciences in Q3 2024 and has held it in 8 quarters since.
Barrow, Hanley, Mewhinney & Strauss's Integra LifeSciences position peaked at $6.24K in Q4 2024.
212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2026, filed 12 Aug 2026.